| Literature DB >> 34562096 |
Cynthia L Gay1,2, Katherine S James1, Marina Tuyishime3, Shane D Falcinelli1,4, Sarah B Joseph1,4, Matthew J Moeser5, Brigitte Allard1, Jennifer L Kirchherr1, Matthew Clohosey1, Samuel L M Raines1, David C Montefiori3, Xiaoying Shen3, Robert J Gorelick6, Lucio Gama7, Adrian B McDermott7, Richard A Koup7, John R Mascola7, Michelle Floris-Moore2, JoAnn D Kuruc1,2, Guido Ferrari3, Joseph J Eron1,2, Nancie M Archin1,2, David M Margolis1,2,4.
Abstract
We tested the combination of a broadly neutralizing HIV antibody with the latency reversal agent vorinostat (VOR). Eight participants received 2 month-long cycles of VRC07-523LS with VOR. Low-level viremia, resting CD4+ T-cell-associated HIV RNA (rca-RNA) was measured, and intact proviral DNA assay (IPDA) and quantitative viral outgrowth assay (QVOA) were performed at baseline and posttreatment. In 3 participants, IPDA and QVOA declines were accompanied by significant declines of rca-RNA. However, no IPDA or QVOA declines clearly exceeded assay variance or natural decay. Increased resistance to VRC07-523LS was not observed. This combination therapy did not reduce viremia or the HIV reservoir. Clinical Trials Registration. NCT03803605.Entities:
Keywords: HIV latency; broadly neutralizing antibody; latency reversal
Mesh：
Substances：
Year: 2022 PMID： 34562096 PMCID： PMC8889279 DOI： 10.1093/infdis/jiab487
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 7.759